RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids. Keloids are raised scars formed from benign fibrous tissue. Sensus’ SRT-100™ device is based on a proprietary low-energy x-ray technology. Chindex Medical, a medical device distributor owned by FosunPharma, has been distributing the SRT-100 device in China for non-melanoma skin cancers since 2014. It plans to emphasize use of the device to prevent keloids associated with Cesarean sections.
Source: ChinaBio Today
